Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
Director departure
Aprea Therapeutics, Inc. (APRE) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
08/24/2023 8-K Resignation/termination of a director
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
07/11/2023 ARS Form ARS - Annual Report to Security Holders:
07/11/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
07/05/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/08/2023 8-K Quarterly results
04/18/2023 8-K Quarterly results
03/13/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
03/03/2023 SC 13G HIRSCHMAN ORIN reports a 9.2% stake in ApreaTherapeutics, Inc.
03/01/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement"
02/24/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, between Aprea Therapeutics, Inc. and Maxim Group LLC",
"Opinion of DLA Piper LLP (US)",
"Aprea Therapeutics Announces Proposed Public Offering of Common Stock DOYLESTOWN, Pa., February 22, 2023 Aprea Therapeutics, Inc. , a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response pathways, today announced it has commenced an underwritten public offering of shares of its common stock. All shares of common stock in the offering are to be sold by Aprea. In addition, Aprea intends to grant the underwriter in the offering a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering at the public offering price, less underwriting discounts and commissions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering ma...",
"Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock DOYLESTOWN, PA., February 22, 2023 Aprea Therapeutics, Inc. , a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response pathways, today announced the pricing of its previously announced underwritten public offering of 1,050,000 shares of its common stock at a public offering price of $5.25 per share. Gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $5.5 million before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Aprea has granted the underwriter a 30-day option to pu..."
02/24/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
02/22/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
02/13/2023 8-K Quarterly results
02/10/2023 8-K Quarterly results
01/30/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Aprea Therapeutics Appoints John Hamill as Chief Financial Officer DOYLESTOWN, PA, January 30, 2023 – Aprea Therapeutics, Inc. , a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response pathways, today announced the appointment of John Hamill as Chief Financial Officer. Mr. Hamill joins Aprea with more than 30 years of finance and accounting experience. “Aprea Therapeutics has made substantial progress and is now reaching an exciting inflection point given the advancement of our ATR inhibitor in Phase 1 human clinical trials. I look forward to working closely with John to advance our mission of finding ways to revolutionize the treatment of cancer for patients in need of new therapies,” said Oren Gilad, Ph.D., Presi..."
01/26/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Exhibit 99.1",
"2 Understanding DDRi’s In the Clinic: Why is Toxicity Such a Big Issue? January 2023"
01/09/2023 8-K Quarterly results
12/15/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
11/17/2022 8-K Quarterly results
11/16/2022 8-K Quarterly results
11/15/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
11/09/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/09/2022 8-K Quarterly results
10/26/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
10/11/2022 PRE 14A Form PRE 14A - Other preliminary proxy statements:
09/16/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
09/02/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/19/2022 8-K Quarterly results
08/12/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/11/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy